

PROVECTUS BIOPHARMACEUTICALS, INC.

Form 4

March 31, 2016

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Koe Jan

(Last) (First) (Middle)

1204 E. CENTRAL ROAD,, SUITE 100

(Street)

ARLINGTON HEIGHTS, IL 60005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS
BIOPHARMACEUTICALS, INC.
[PVCT]

3. Date of Earliest Transaction
(Month/Day/Year)
03/29/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)				
				Code	V	Amount	(A) or (D)	Price			
Common Stock	03/29/2016		O ⁽¹⁾		100,000	A		\$ 1.25 <u>(1)</u>	686,300	D	
Common Stock	03/29/2016		O ⁽¹⁾		100,000	A		\$ 1.25 <u>(1)</u>	786,300	D	
Common Stock									150,000	I	By Vekoe Partners LLC

Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying Security (Instr. 3 and 4)
					V	(A)	(D)	Date Exercisable	Expiration Date	
Common Stock Warrants (right to buy)	\$ 1.25 ⁽¹⁾	03/29/2016		O ⁽¹⁾		100,000		06/28/2012	04/15/2016	Common Stock
Common Stock Warrants (right to buy)	\$ 0.85	03/29/2016		O ⁽¹⁾		100,000		03/29/2016	06/19/2020	Common Stock
Common Stock Warrants (right to buy)	\$ 1.25 ⁽¹⁾	03/29/2016		O ⁽¹⁾		100,000		04/20/2011	04/20/2016	Common Stock
Common Stock Warrants (right to buy)	\$ 0.85	03/29/2016		O ⁽¹⁾		100,000		03/29/2016	06/19/2020	Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Koe Jan 1204 E. CENTRAL ROAD, SUITE 100 ARLINGTON HEIGHTS, IL 60005		X		

Signatures

/s/ Jan E. Koe

03/31/2016

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) On March 29, 2016, the reporting person exercised an aggregate of 200,000 warrants pursuant to the Issuer's warrant exchange offer, at a discounted exercise price of \$0.50 per share, which exercise consisted of: (i) an exercise of 100,000 shares pursuant to a warrant issued on June 28, 2012, with an original exercise price of \$1.25 per share and (ii) an exercise of 100,000 shares pursuant to a warrant issued on September 20, 2013, with an original exercise price of \$1.25 per share. Under the terms of the warrant exchange offer, holders received, in addition to the common stock acquired upon exercise of their existing warrants, an equal number of new warrants to purchase the same number of shares of the Issuer's common stock at an exercise price of \$0.85 per share that will expire June 19, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.